Live Analyst Rating Changes 16810 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Samantha Semenkow
Citi

Samantha Semenkow

Citi
Wall Street Analyst
★★☆☆☆
#2633
on 13Foresight · ranked by our own returns
41%
Success Rate
-2.5%
Average Return
15 of 37 calls profitable · -9.6% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 41% of Samantha Semenkow's ratings turned a profit when each position was held for 1 year — averaging -2.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

81 Buy 6 Hold 3 Sell
Samantha's Stock Coverage 26 ratings · 2026-08-04
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
BIOA
BioAge Labs, Inc.
 Jul 31, 2026 BUY Strong Buy
+304.3% avg upside
9 analysts
$52.00
475.17% Upside
 +0.0% ·
WVE
Wave Life Sciences
 Jul 31, 2026 BUY Strong Buy
+269.3% avg upside
28 analysts
$19.00
244.82% Upside
 +4.2% ·
AGIO
Agios Pharma
 Jul 31, 2026 BUY Strong Buy
+101.5% avg upside
29 analysts
$52.00
73.19% Upside
 +0.0% ·
ARGX
Argenx Se
 Jul 24, 2026 BUY Strong Buy
-7.3% avg upside
47 analysts
$1203.00
40.92% Upside
 -7.0% ·
NKTR
Nektar Therapeutics
 Jul 21, 2026 BUY Buy
+6.5% avg upside
26 analysts
$151.00
113.76% Upside
 +3.9% ·
LRMR
Larimar Therapeutics
 Jun 30, 2026 BUY Strong Buy
+363.7% avg upside
22 analysts
$14.00
266.50% Upside
 +23.9% ·
IMVT
Immunovant
 Jun 30, 2026 BUY Strong Buy
+1.4% avg upside
24 analysts
$61.00
57.86% Upside
 +0.2% ·
SABS
SAB Biotherapeutics
 Jun 15, 2026 BUY Strong Buy
+192.6% avg upside
14 analysts
$11.00
208.08% Upside
 -11.5% ·
CGEM
Cullinan Management
 Jun 10, 2026 BUY Strong Buy
+107.5% avg upside
15 analysts
$33.00
100.01% Upside
 +34.8% ·
ROIV
Roivant Sciences
 May 21, 2026 BUY Strong Buy
-2.7% avg upside
17 analysts
$42.00
23.93% Upside
 +9.8% ·
BEAM
Beam Therapeutics
 May 13, 2026 BUY Strong Buy
+100.6% avg upside
25 analysts
$68.00
166.53% Upside
 -19.9% ·
SYRE
Spyre Therapeutics
 May 06, 2026 BUY Strong Buy
-11.0% avg upside
23 analysts
$97.00
1.43% Downside
 +43.8% ·
ALLO
Allogene Therapeutics
 Apr 09, 2026 BUY Strong Buy
+718.8% avg upside
28 analysts
$4.00
112.80% Upside
 -34.0% ·
BHVN
Biohaven Ltd.
 Apr 02, 2026 BUY Buy
+70.2% avg upside
25 analysts
$17.00
25.86% Upside
 +36.4% ·
VYGR
Voyager Therapeutics
 Mar 23, 2026 BUY Strong Buy
+374.2% avg upside
23 analysts
$11.00
262.97% Upside
 -21.9% ·
MLTX
MoonLake Immunotherapeutics
 Mar 20, 2026 SELL Strong Buy
+62.8% avg upside
20 analysts
$6.00
67.52% Downside
 -13.3% ·
RYTM
Rhythm Pharmaceuticals
 Mar 20, 2026 BUY Strong Buy
+18.4% avg upside
19 analysts
$142.00
43.15% Upside
 +13.5% ·
GPCR
Structure Therapeutics, Inc. Sponsored ADR
 Mar 16, 2026 BUY Strong Buy
+115.3% avg upside
17 analysts
$100.00
108.19% Upside
 -15.2% ·
SANA
Sana Biotechnology
 Mar 04, 2026 BUY Strong Buy
+215.9% avg upside
14 analysts
$12.00
283.35% Upside
 -16.8% ·
PRME
Prime Medicine, Inc.
 Nov 11, 2025 HOLD Strong Buy
+238.9% avg upside
16 analysts
$4.25
45.63% Upside
 -22.7% ·
CABA
Cabaletta Bio
 Oct 10, 2025 BUY Strong Buy
+420.7% avg upside
16 analysts
$10.00
273.07% Upside
 +12.9% ·
EDIT
Editas Medicine
 Mar 06, 2025 BUY Buy
+423.7% avg upside
33 analysts
$5.00
93.72% Upside
 +12.4% ·
FTH
Faeth Therapeutics
 Jun 03, 2024 BUY Strong Buy
+63.9% avg upside
15 analysts
$4.00
85.38% Downside
 -53.6% ·
NMTRQ
9 Meters Biopharma
 May 18, 2023 HOLD Buy
+3234374900.0% avg upside
11 analysts
$0.75
74999899.99% Upside
 · ·
ZLAB
Zai Lab
 May 11, 2023 BUY Strong Buy
+222.7% avg upside
13 analysts
$130.00
611.60% Upside
 -45.3% ·
ARDX
Ardelyx
 Jul 21, 2021 BUY Strong Buy
+181.0% avg upside
21 analysts
$7.00
41.47% Upside
 -62.6% ·
🔒 21 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Samantha Semenkow — Frequently Asked Questions
How accurate are Samantha Semenkow's stock ratings?
Based on the calls 13Foresight could measure, about 41% of Samantha's ratings were profitable over a one-year hold, with an average return of -2.8% per rating, or -9.9% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Samantha ranked on 13Foresight?
Samantha Semenkow is currently ranked #2633 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Samantha cover?
Samantha most recently has ratings on BIOA, WVE, AGIO, ARGX, NKTR, LRMR, IMVT, SABS, CGEM, ROIV, BEAM, SYRE and 14 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.